- Home
- CRAN vs AUTL Comparison
CRAN vs AUTL Comparison
Compare CRAN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAN | AUTL |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.9M | 407.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRAN | AUTL |
|---|---|---|
| Price | $10.07 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 39.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.90 | $1.18 |
| 52 Week High | $10.10 | $2.70 |
Technical Indicators
Market Signals| Indicator | CRAN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 44.26 |
| Support Level | $9.97 | $1.27 |
| Resistance Level | $10.10 | $1.73 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 76.83 | 7.87 |
Price Performance
Historical ComparisonAbout CRAN Crane Harbor Acquisition Corp. II Class A Ordinary Shares
Crane Harbor Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.